This project aims to generate an algae extract with neuro- and cardio-protective activity by means of selected microalgae, hyper-producers of long-chain omega-3 polyunsaturated fatty acids and antioxidants. Through the massive cultivation of these microalgae we seek in the medium term to produce an ingredient for food supplements, nutraceuticals, and in the long term, to evaluate their potential use in a pharmacological context.

– The extract has a neuroprotective, anti-aging and positive effect on neurodegenerative diseases, including a rare metabolic disease that may allow it to follow an accelerated regulatory approval pathway before the US FDA.
– Its production sequesters CO2 and produces oxygen, characteristics that mitigate the accumulation of greenhouse gases in the atmosphere. It is sustainable.
– It is not limited by fishing quotas, nor is it affected by cyclical or long-term weather patterns, nor by the regenerative capacity of fish stocks.
– It contains antioxidants, which in addition to their properties in the body help preserve the product.
– Contains EPA, which prevents cardiovascular and inflammatory diseases.
– It does not have the unpleasant odor of fish oil.

The global market for algal omega-3s, 2022 was USD 1.1 billion and is projected to be USD 2.3 billion by 2030, with a CAGR of 10.6% for the period 2022-2030 . Within this market we believe our products target a market of USD 538 million (2022) associated with Omega-3 based dietary supplements and functional foods globally.
Our products suitable for a vegan audience suggest an obtainable market of USD 1 million per year.
From a regulatory point of view, we use a strain that is a variant of a microalgae species safe for human consumption, and although the FDA does not grant functionality seals to any supplement in the USA, it regulates good manufacturing practices. Therefore, it is feasible to think of launching a product of this nature on the market in the medium term, without the need to comply with sophisticated regulatory requirements, which would allow generating income in a reasonable period of time. In the long term, in order to become a pharmaceutical product, it would be necessary to go through the regulatory approval processes typical for this type of product, which would require an external investment of a different magnitude.